Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High – Still a Buy?

Roivant Sciences Ltd. (NASDAQ:ROIV)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $25.49 and last traded at $24.7320, with a volume of 3598048 shares changing hands. The stock had previously closed at $21.14.

Roivant Sciences News Summary

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant/Priovant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis — a potentially high-value, unmet-need dermatology indication — which investors view as a major clinical validation and upside driver for ROIV. Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results
• Positive Sentiment: Pulmovant (a Roivant company) completed enrollment in a Phase 2 study of mosliciguat for PH‑ILD — a milestone that derisks that program’s near-term timeline and supports pipeline optionality. Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study
• Neutral Sentiment: Market and media coverage amplified the clinical readout, with multiple outlets reporting premarket/early gains and calling the brepocitinib result a potential “blockbuster” scenario — driving momentum but not yet changing consensus commercial forecasts. Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data
• Neutral Sentiment: Analysts and outlets were already watching Roivant ahead of these readouts; previews and earnings‑focused pieces continue to circulate and may keep trading volatile as investors reassess program valuations and timelines. All eyes on Roivant earnings ahead of key drug trial readouts
• Negative Sentiment: Roivant’s latest quarter showed mixed financials: revenue missed estimates and EPS/quarterly metrics were reported as a miss by some sources, highlighting continued cash burn and near-term commercialization uncertainty — factors that could limit sustained upside absent further clinical or commercial clarity. Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Leerink Partners lifted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. HC Wainwright increased their target price on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research report on Thursday, December 18th. Finally, Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Trading Up 18.5%

The company has a market cap of $17.42 billion, a PE ratio of -45.05 and a beta of 1.22. The firm has a 50 day moving average of $21.97 and a two-hundred day moving average of $17.67.

Insider Activity

In other news, CFO Richard Pulik sold 406,731 shares of Roivant Sciences stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the transaction, the chief financial officer owned 239,413 shares of the company’s stock, valued at $5,370,033.59. The trade was a 62.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the sale, the insider owned 36,350,621 shares of the company’s stock, valued at approximately $798,259,637.16. This represents a 5.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 12,132,392 shares of company stock valued at $262,349,645. 10.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its holdings in shares of Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after acquiring an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Roivant Sciences by 10.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,261 shares of the company’s stock worth $296,000 after purchasing an additional 2,385 shares during the period. KLP Kapitalforvaltning AS raised its stake in Roivant Sciences by 6.6% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 76,100 shares of the company’s stock valued at $858,000 after buying an additional 4,700 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Roivant Sciences by 28.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 43,612 shares of the company’s stock worth $492,000 after acquiring an additional 9,548 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.